EUCTR2008-001632-13-IT进行中（未招募）不适用
Continuous vs intermittent weekly docetaxel in the elderly patient with advanced and hormone-refractory prostate cancer: a randomized phase II study - ND
EGA ITALIANA PER LA LOTTA CONTRO I TUMORI0 个研究点开始时间: 2009年3月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •- Hormone-refractory prostate cancer in biochemical remission following two cycles of chemotherapy with weekly docetaxel
- •- Age > 70 years
- •- ECOG PS < 2
- •- No prior chemotherapy
- •- No history of other malignancies
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Brain metastases
- •- Uncontrolled infections
- •- Heart failure or ischemic heart disease
研究者
相似试验
已完成
不适用
Weekly administration of (bi-)daily Oral Docetaxel in combination with Ritonavirmalignancy10027655cancerNL-OMON39193Antoni van Leeuwenhoek Ziekenhuis48
已完成
不适用
Weekly administration of oral docetaxel in combination with ritonavir for the treatment of a variety of tumour typesCancerISRCTN32770468The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI/ALH) (Netherlands)78
招募中
不适用
Weekly administration of Oral Docetaxel in combination with Ritonaviradvanced cancer10027656NL-OMON39153Antoni van Leeuwenhoek Ziekenhuis100
已完成
不适用
Randomized study of docetaxel or weekly paclitaxel followed by 5FU + epirubicin + cyclophosphamide as preoperative chemotherapy for primary breast cancerprimary breast cancerJPRN-UMIN000000916kobe breast cancer oncology group50
已完成
2 期
Randomized phase II syudy of weekly docetaxel versus S-1 and concurrent radiothrapy for stage III and IV laryngeal, oropharyngeal, and hypopharyngeal cancer in elderly patients or patients with complicationslaryngeal, oropharyngeal, and hypopharyngeal cancerJPRN-UMIN000001144study group of chemoradiotherapy of the head and neck cancer60